Compare Glenmark Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DIVIS LABORATORIES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DIVIS LABORATORIES GLENMARK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 9.6 34.2 28.2% View Chart
P/BV x 1.4 6.4 21.6% View Chart
Dividend Yield % 0.7 1.0 76.1%  

Financials

 GLENMARK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
GLENMARK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7121,639 43.4%   
Low Rs4841,115 43.4%   
Sales per share (Unadj.) Rs349.6186.3 187.6%  
Earnings per share (Unadj.) Rs32.851.0 64.3%  
Cash flow per share (Unadj.) Rs44.357.3 77.3%  
Dividends per share (Unadj.) Rs2.0016.00 12.5%  
Dividend yield (eoy) %0.31.2 28.8%  
Book value per share (Unadj.) Rs198.6261.8 75.9%  
Shares outstanding (eoy) m282.17265.47 106.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.77.4 23.1%   
Avg P/E ratio x18.227.0 67.5%  
P/CF ratio (eoy) x13.524.0 56.1%  
Price / Book Value ratio x3.05.3 57.2%  
Dividend payout %6.131.4 19.4%   
Avg Mkt Cap Rs m168,625365,592 46.1%   
No. of employees `00012.011.8 101.6%   
Total wages/salary Rs m20,5615,423 379.2%   
Avg. sales/employee Rs Th8,196.04,175.1 196.3%   
Avg. wages/employee Rs Th1,708.1457.7 373.2%   
Avg. net profit/employee Rs Th768.51,141.8 67.3%   
INCOME DATA
Net Sales Rs m98,65549,463 199.5%  
Other income Rs m2,0811,556 133.7%   
Total revenues Rs m100,73651,019 197.4%   
Gross profit Rs m15,85818,718 84.7%  
Depreciation Rs m3,2591,689 193.0%   
Interest Rs m3,34635 9,559.7%   
Profit before tax Rs m11,33518,551 61.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7565,023 74.8%   
Profit after tax Rs m9,25013,527 68.4%  
Gross profit margin %16.137.8 42.5%  
Effective tax rate %33.127.1 122.4%   
Net profit margin %9.427.3 34.3%  
BALANCE SHEET DATA
Current assets Rs m66,96846,501 144.0%   
Current liabilities Rs m40,2118,468 474.9%   
Net working cap to sales %27.176.9 35.3%  
Current ratio x1.75.5 30.3%  
Inventory Days Days83131 63.7%  
Debtors Days Days8186 94.6%  
Net fixed assets Rs m33,32225,797 129.2%   
Share capital Rs m282531 53.2%   
"Free" reserves Rs m55,77068,962 80.9%   
Net worth Rs m56,05269,493 80.7%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88880,383 165.3%  
Interest coverage x4.4531.0 0.8%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.70.6 120.6%   
Return on assets %9.516.9 56.2%  
Return on equity %16.519.5 84.8%  
Return on capital %17.826.7 66.6%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m62,99841,238 152.8%   
Fx outflow Rs m22,85912,405 184.3%   
Net fx Rs m40,14028,833 139.2%   
CASH FLOW
From Operations Rs m13,2429,543 138.8%  
From Investments Rs m-6,990-6,854 102.0%  
From Financial Activity Rs m-7,387-2,459 300.4%  
Net Cashflow Rs m-2,971230 -1,293.9%  

Share Holding

Indian Promoters % 48.3 52.0 92.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.8 58.5%  
FIIs % 34.4 19.0 181.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   56,727 31,796 178.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  FRESENIUS KABI ONCO.  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling Pressure, Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

Indian share markets closed on a negative note yesterday amid weak global cues and disappointing domestic factory output data.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS